Erratum: The metabolic co-regulator PGC1α suppresses prostate cancer metastasis (Nature Cell Biology (2016) 18 (645-656) DOI: 10.1038/ncb3357);The metabolic co-regulator PGC1α suppresses prostate cancer metastasis

Nature Cell Biology

Volumn 18, Issue 6, 2016, Pages 645-656

  Torrano, Veronica ^a   Valcarcel Jimenez, Lorea ^a   Cortazar, Ana Rosa ^a   Liu, Xiaojing ^b   Urosevic, Jelena ^c   Castillo Martin, Mireia ^d,e   Fernández Ruiz, Sonia ^f   Morciano, Giampaolo ^a   Caro Maldonado, Alfredo ^c   Guiu, Marc ^a   Zúñiga García, Patricia ^g   Graupera, Mariona ^c   Bellmunt, Anna ^h   Pandya, Pahini ⁱ   Lorente, Mar ^a   Martín Martín, Natalia ^a   David Sutherland, James ^a   Sanchez Mosquera, Pilar ^a   Bozal Basterra, Laura ^a   Zabala Letona, Amaia ^a   Arruabarrena Aristorena, Amaia ^a   Berenguer, Antonio ^c   Embade, Nieves ^a   Ugalde Olano, Aitziber ^j   Lacasa Viscasillas, Isabel ^j   Loizaga Iriarte, Ana ^j   Unda Urzaiz, Miguel ^j   Schultz, Nikolaus ^k   Aransay, Ana Maria ^a,l   Sanz Moreno, Victoria ^h   Barrio, Rosa ^a   Velasco, Guillermo ⁱ   Pinton, Paolo ^f   Cordon Cardo, Carlos ^d   Locasale, Jason W ^b   Gomis, Roger R ^c,m   Carracedo, Arkaitz ^a,n,o   more..

^a CIC BIOGUNE   (Spain)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e CHAMPALIMAUD FOUNDATION   (Portugal)

^f UNIVERSITY OF FERRARA   (Italy)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

ⁿ BASQUE FOUNDATION FOR SCIENCE   (Spain)

^o UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RELATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ERRALPHA ESTROGEN-RELATED RECEPTOR; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN; PPARGC1A PROTEIN, HUMAN; PPARGC1A PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CONTROLLED STUDY; DATA MINING; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METABOLOMICS; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; TRANSCRIPTION INITIATION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; ENERGY METABOLISM; METABOLISM; METASTASIS; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MITOCHONDRIA; NEOPLASM METASTASIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 84969816000     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3558     Document Type: Erratum

References (77)

1. Loo, J. M. et al. Extracellular metabolic energetics can promote cancer progression. Cell 160, 393-406 (2015).
2. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
3. Vander Heiden, M. G. et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
4. Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227-232 (2013).
5. Yang, M., Soga, T. & Pollard, P. J. Oncometabolites: linking altered metabolism with cancer. J. Clin. Invest. 123, 3652-3658 (2013).
6. Ortega-Molina, A. et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab. 15, 382-394 (2012).
7. Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49-62 (2012).
8. Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008).
9. Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283-296 (2012).
10. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355 (1998).
11. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
12. Majumder, P. K. et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc. Natl Acad. Sci. USA 100, 7841-7846 (2003).
13. Magnon, C. et al. Autonomic nerve development contributes to prostate cancer progression. Science 341, 1236361 (2013).
14. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
15. Nandana, S. & Chung, L. W. Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am. J. Clin. Exp. Urol. 2, 92-101 (2014).
16. Cho, H. et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 4, 318-333 (2014).
17. Mouchiroud, L., Eichner, L. J., Shaw, R. J. & Auwerx, J. Transcriptional coregulators: fine-tuning metabolism. Cell Metab. 20, 26-40 (2014).
18. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811-816 (2004).
19. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
20. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
21. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
22. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
23. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).
24. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406 (2005).
25. Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215-1228 (2015).
26. Lin, J., Handschin, C. & Spiegelman, B. M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361-370 (2005).
27. Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1 and MITF. Cancer Cell 23, 302-315 (2013).
28. Vazquez, F. et al. PGC1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287-301 (2013).
29. LeBleu, V. S. et al. PGC-1 mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992-1003 (2014).
30. LaGory, E. L. et al. Suppression of PGC-1 is critical for reprogramming oxidative metabolism in renal cell carcinoma. Cell Rep. 12, 116-127 (2015).
31. D'Errico, I. et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-(PGC1) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl Acad. Sci. USA 108, 6603-6608 (2011).
32. Sancho, P. et al. MYC/PGC-1 balance determines the metabolic phenotype and plasticity of pancreatic cancer stem cells. Cell Metab. 22, 590-605 (2015).
33. Audet-Walsh, E. et al. The PGC-1/ERR axis represses one-carbon metabolism and promotes sensitivity to anti-folate therapy in breast cancer. Cell Rep. 14, 920-931 (2016).
34. Lin, J. et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1 null mice. Cell 119, 121-135 (2004).
35. Eisele, P. S. & Handschin, C. Functional crosstalk of PGC-1 coactivators and inflammation in skeletal muscle pathophysiology. Semin. Immunopathol. 36, 27-53 (2014).
36. Saint-Geniez, M. et al. PGC-1 regulates normal and pathological angiogenesis in the retina. Am. J. Pathol. 182, 255-265 (2013).
37. Nardella, C., Carracedo, A., Salmena, L. & Pandolfi, P. P. Faithfull modeling of PTEN loss driven diseases in the mouse. Curr. Top. Microbiol. Immunol. 347, 135-168 (2011).
38. Nardella, C. et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22, 2172-2177 (2008).
39. Li, S. et al. Genome-wide coactivation analysis of PGC-1 identifies BAF60a as a regulator of hepatic lipid metabolism. Cell Metab. 8, 105-117 (2008).
40. Tennakoon, J. B. et al. Androgens regulate prostate cancer cell growth via an AMPKPGC-1-mediated metabolic switch. Oncogene 33, 5251-5261 (2014).
41. Shiota, M. et al. Peroxisome proliferator-activated receptor gamma coactivator-1 interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol. Endocrinol. 24, 114-127 (2010).
42. Buijs, J. T. & van der Pluijm, G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 273, 177-193 (2009).
43. Garcia, M. et al. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice. BJU Int. 113, E164-E177 (2014).
44. Feige, J. N. & Auwerx, J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol. 17, 292-301 (2007).
45. Finley, L. W., Zhang, J., Ye, J., Ward, P. S. & Thompson, C. B. SnapShot: cancer metabolism pathways. Cell Metab. 17, e462-466 (2013).
46. Stein, R. A. et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res. 68, 8805-8812 (2008).
47. Gaillard, S. et al. Receptor-selective coactivators as tools to define the biology of specific receptor-coactivator pairs. Mol. Cell 24, 797-803 (2006).
48. Chang, C. Y. et al. The metabolic regulator ERR, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 20, 500-510 (2011).
49. Piskounova, E. et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186-191 (2015).
50. Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464 (2011).
51. Carracedo, A. et al. A metabolic prosurvival role for PML in breast cancer. J. Clin. Invest. 122, 3088-3100 (2012).
52. Schafer, Z. T. et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109-113 (2009).
53. Arroyo-Berdugo, Y. et al. Involvement of ANXA5 and ILKAP in susceptibility to malignant melanoma. PLoS ONE 9, e95522 (2014).
54. Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144, 187-199 (2011).
55. Chen, Z. et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci. Signal 2, ra44 (2009).
56. Nardella, C. et al. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal 2, ra2 (2009).
57. Guiu, M., Arenas, E. J., Gawrzak, S., Pavlovic, M. & Gomis, R. R. Mammary cancer stem cells reinitiation assessment at the metastatic niche: The lung and bone. Methods Mol. Biol. 1293, 221-229 (2015).
58. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
59. Ugalde-Olano, A. et al. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods 77-78, 25-30 (2015).
60. Finley, L. W. et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1 destabilization. Cancer Cell 19, 416-428 (2011).
61. Caro-Maldonado, A. et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J. Immunol. 192, 3626-3636 (2014).
62. Wojtala, A. et al. Methods to monitor ROS production by fluorescence microscopy and fluorometry. Methods Enzymol. 542, 243-262 (2014).
63. Ittmann, M. et al. Animal models of human prostate cancer: The consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 73, 2718-2736 (2013).
64. Liu, X. et al. High resolution metabolomics with acyl-CoA profiling reveals widespread remodeling in response to diet. Mol. Cell. Proteomics 14, 1489-1500 (2015).
65. Liu, X., Ser, Z. & Locasale, J. W. Development and quantitative evaluation of a highresolution metabolomics technology. Anal. Chem. 86, 2175-2184 (2014).
66. Shestov, A. A. et al. Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. eLife 3, e03342 (2014).
67. Rodriguez, R. M. et al. Regulation of the transcriptional program by DNA methylation during human alphabeta T-cell development. Nucleic Acids Res. 43, 760-774 (2015).
68. Bergmann, R., Ludbrook, J. & Spooren, W. P. J. M. Statistical computing and graphics: different outcomes of the Wilcoxon-Mann-Whitney test from different statistics packages. Am. Statistician 54, 72-77 (2000).
69. Quinn, G. & Keough, M. Experimental Design and Data Analysis for Biologists (Cambridge Univ. Press, 2002).
70. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22, doi:10.1016/j.ccr.2010.05.026 (2010).
71. Varambally, S. et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8, 393-406, doi:10.1016/j.ccr.2005.10.001 (2005).
72. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39, 41-51, doi:10.1038/ng1935 (2007).
73. Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243, doi:10.1038/nature11125 (2012).
74. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101, 811-816, doi:10.1073/pnas.0304146101 (2004).
75. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401-404, doi:10.1158/2159-8290.CD-12-0095 (2012).
76. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1, doi:10.1126/scisignal.2004088 (2013).
77. Stein, R. A. et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 68, 8805-8812, doi:10.1158/0008-5472.CAN-08-1594 (2008).